U.S. License Holder:
Regeneron Pharmaceuticals
Date of License:
October-14-2020
Last Update:
Dec-08-2024
FDA-Approved Indications
INMAZEB (atoltivimab; odesivimab; maftivimab) is a combination of Orthoebolavirus zairense glycoprotein-directed human monoclonal antibodies (atoltivimab, maftivimab, and odesivimab), indicated for the treatment of infection caused by Orthoebolavirus zairense in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Orthoebolavirus zairense infection.